Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Fulvestrant Plus Palbociclib vs Fulvestrant Plus Placebo for HR+, HER2─ Metastatic Breast Cancer That Progressed on Endocrine Therapy
- Fosaprepitant Effectively Reduces Emesis During Chemotherapy in Cervical Cancer Patients
- Exemestane Plus Bevacizumab Maintenance in Metastatic Breast Cancer
- Pathologic Complete Response to Neoadjuvant Therapy and Long-Term Outcomes in HER2 Breast Cancer
- Paclitaxel and Carboplatin in Ovarian Cancer
- Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients With HER2-Positive Breast Cancer
- Late Reintroduction of Letrozole as Adjuvant Endocrine Therapy in Hormone Receptor–Positive Breast Cancer
- Nab-Paclitaxel vs Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer
- Radiotherapy After Breast-Conserving Surgery for DCIS
- Neratinib for HER2-Positive Breast Cancer and Brain Metastases